Evidence map›Paper›PMID 33578296›Full record

ArticleDrug and alcohol dependence2021

Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.

Bradley D Stein, Christopher M Jones, Rosanna Smart, Flora Sheng, Mark Sorbero

Open access · greenAbstract read
In one paragraph

Article in Drug and alcohol dependence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Bradley D SteinRAND Corporation, 4570 Fifth Avenue, Suite 600, Pittsburgh, PA, USA; University of Pittsburgh School of Medicine, 3550 Terrace Street, Pittsburgh, PA, USA. Electronic address: stein@rand.org.
Christopher M JonesCenters for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, USA.
Rosanna SmartRAND Corporation, 1776 Main Street, Santa Monica, CA, USA.
Flora ShengRAND Corporation, 1200 South Hayes Street, Arlington, VA, USA.
Mark SorberoRAND Corporation, 4570 Fifth Avenue, Suite 600, Pittsburgh, PA, USA.
RAND Corporation · USCenters for Disease Control and Prevention · USUniversity of Pittsburgh · US

Funding

Optimal Methods for Estimating Policy Effect Heterogeneity in Opioid Policy ResearchP50DA046351 · NIDA · RAND CORPORATION · PI BRADLEY D STEIN · 2018 to 2026
$20.8M
Scientific and Technical CoreP2CHD041022 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Martha Jane Bailey · 2016 to 2026
$6.9M
CALIFORNIA CENTER FOR POPULATION TRAINING PROGRAMT32HD007545 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HIRAM BELTRAN-SANCHEZ, Megan M Sweeney · 2001 to 2026
$4.1M
Quality of Medication Treatment for Opioid Use Disorder in Medicaid-enrollees: The Effects of State Policies and IntiativesR01DA045800 · NIDA · RAND CORPORATION · PI STEIN, BRADLEY D · 2018 to 2022
$2.9M
State Naloxone Policies: Exploring Effects of Implementation on EMS and Community Bystander UseR21DA045950 · NIDA · RAND CORPORATION · PI SMART, ROSANNA · 2018 to 2019
$474k
NICHD NIH HHS P2C HD041022NICHD NIH HHS T32 HD007545NIDA NIH HHS P50 DA046351NIDA NIH HHS R01 DA045800NIDA NIH HHS R21 DA045950
6 · The paper itself

Abstract

backgroundPrescribing naloxone to patients at increased opioid overdose risk is a key component of opioid overdose prevention efforts, but little is known about naloxone fills among patients receiving buprenorphine for opioid use disorder, one such high risk group.

methodsThis retrospective cross-sectional study used de-identified pharmacy claims representing 90% of all prescriptions filled at retail pharmacies in 50 states and the District of Columbia. We performed a multivariable logistic regression to examine filled naloxone prescriptions among patients receiving buprenorphine treatment and assessed how filled naloxone prescriptions vary by patient, prescriber, and community characteristics.

resultsFilled naloxone prescriptions occurred among 4.5% of buprenorphine treatment episodes. Episodes paid through Medicaid (aOR 2.40, 95%CI 2.33-2.47) and Medicare (aOR 1.53, 95%CI 1.46-1.60) had higher odds of filled naloxone prescriptions than commercial insurance episodes. Compared to episodes where the primary prescriber was an adult primary care physician, odds of filling a naloxone prescription were higher among episodes prescribed by addiction specialists (aOR 1.30, 95% CI 1.24-1.37) and physician assistants/nurse practitioners (aOR 1.57, 95% CI 1.53-1.61).

conclusionsPrescribing naloxone to patients receiving buprenorphine represents a tangible clinical action that can be taken to help prevent opioid overdose deaths. However, despite recommendations to co-prescribe naloxone to patients at increased risk for opioid overdose, rates of filling naloxone prescriptions remain low among patients dispensed buprenorphine. States, insurers, and health systems should consider implementing strategies to facilitate increased co-prescribing of naloxone to at-risk individuals.

Indexed as

AdultAnalgesics, OpioidBuprenorphineBuprenorphine, Naloxone Drug CombinationCross-Sectional StudiesDistrict of ColumbiaFemaleHumansMaleMedicaidMedicareMiddle AgedNaloxoneOpiate OverdoseOpioid-Related DisordersPharmaciesAnalgesics, OpioidBuprenorphineBuprenorphine, Naloxone Drug CombinationNaloxoneBuprenorphineNaloxoneOpioidsOverdoseTreatment

Identifiers

PMID33578296
PMCPMC8027950
OpenAlexW3126199671

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.